Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line

Purpose: Deregulated expression of the Aurora kinases (Aurora-A, -B and -C) is thought to be involved in cell malignant transformation and genomic instability in several cancer types. Over the last decade, a number of small molecule inhibitors of Aurora kinases have been developed, which have proved to efficiently restrain malignant cell growth and tumorigenicity. Regarding medullary thyroid carcinoma (MTC), we previously showed the efficacy of a pan-Aurora kinase inhibitor (MK-0457) in impairing growth and survival of the MTC-derived cell line TT. In the present study, we sought to establish if one of the Aurora kinases might represent a preferential inhibitor target for MTC. Methods: The effects of selective inhibitors of Aurora-A (MLN8237) and Aurora-B (AZD1152) were analyzed on TT cell proliferation, apoptosis, cell cycle and ploidy. Results: The two inhibitors reduced TT cell proliferation in a time- and dose-dependent manner, with IC50 19.0±2.4 nM for MLN8237 and 401.6±44.1 nM for AZD1152. Immunofluorescence experiments confirmed that AZD1152 inhibited phosphorylation of histone H3(Ser10) by Aurora-B, while did not affect Aurora-A autophosphorylation. MLN8237 inhibited Aurora-A autophosphorylation as expected, but at concentrations required to achieve the maximum antiproliferative effects it also abolished H3(Ser10) phosphorylation. Cytofluorimetry experiments showed that both inhibitors induced accumulation of cells in G2/M phase and increased the subG0/G1 fraction and polyploidy. Finally, both inhibitors triggered apoptosis. Conclusions: We demonstrated that inhibition of either Aurora-A or Aurora-B has anti-proliferative effects on TT cells, and thus it would be worthwhile to further investigate the therapeutical potential of Aurora kinase inhibitors in MTC treatment.